"Receptors, CXCR4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
CXCR receptors with specificity for CXCL12 CHEMOKINE. The receptors may play a role in HEMATOPOIESIS regulation and can also function as coreceptors for the HUMAN IMMUNODEFICIENCY VIRUS.
| Descriptor ID |
D019718
|
| MeSH Number(s) |
D12.776.543.750.695.160.500.400 D12.776.543.750.705.852.125.500.400 D12.776.543.750.830.700.650
|
| Concept/Terms |
Receptors, CXCR4- Receptors, CXCR4
- LESTR Receptor
- CXC Chemokine Receptor 4
- Fusin
- CXCR4 Receptor
- Receptor, CXCR4
- CXCR4 Receptors
- Leukocyte-Derived Seven-Transmembrane Domain Receptor
- Leukocyte Derived Seven Transmembrane Domain Receptor
- Receptor, LESTR
|
Below are MeSH descriptors whose meaning is more general than "Receptors, CXCR4".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Chemokine [D12.776.543.750.695.160]
- Receptors, CXCR [D12.776.543.750.695.160.500]
- Receptors, CXCR4 [D12.776.543.750.695.160.500.400]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Chemokine [D12.776.543.750.705.852.125]
- Receptors, CXCR [D12.776.543.750.705.852.125.500]
- Receptors, CXCR4 [D12.776.543.750.705.852.125.500.400]
- Receptors, Virus [D12.776.543.750.830]
- Receptors, HIV [D12.776.543.750.830.700]
- Receptors, CXCR4 [D12.776.543.750.830.700.650]
Below are MeSH descriptors whose meaning is more specific than "Receptors, CXCR4".
This graph shows the total number of publications written about "Receptors, CXCR4" by people in this website by year, and whether "Receptors, CXCR4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 0 | 3 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 4 | 6 |
| 2017 | 2 | 4 | 6 |
| 2018 | 3 | 2 | 5 |
| 2019 | 3 | 1 | 4 |
| 2020 | 3 | 2 | 5 |
| 2021 | 5 | 2 | 7 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, CXCR4" by people in Profiles.
-
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenstr?m macroglobulinemia: a pooled analysis. Blood Adv. 2025 Sep 23; 9(18):4705-4715.
-
Disruption of the Nucleolin-CXCR4 interaction by the DNA aptamer HY-4 halts colorectal cancer metastasis. Mol Ther. 2025 Oct 01; 33(10):4904-4922.
-
Diagnosis and Management of Waldenstrom's Macroglobulinemia. Hematol Oncol. 2025 Jun; 43 Suppl 2:e70071.
-
From the archives of MD Anderson Cancer Center: Composite mantle cell lymphoma and lymphoplasmacytic lymphoma involving bone marrow at presentation. Ann Diagn Pathol. 2024 Dec; 73:152372.
-
How I use genomics and BTK inhibitors in the treatment of Waldenstr?m macroglobulinemia. Blood. 2024 04 25; 143(17):1702-1712.
-
Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy. Gastroenterology. 2024 Jul; 167(2):298-314.
-
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Res. 2023 06 06; 25(1):62.
-
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia. 2023 06; 37(6):1379-1383.
-
Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients. J Clin Immunol. 2022 11; 42(8):1748-1765.
-
A British view on the management of Waldenstr?m macroglobulinemia. Br J Haematol. 2022 04; 197(2):133-134.